摘要
目的:研究放化疗联合贝伐珠单抗靶向治疗晚期卵巢癌患者的临床效果。方法:设计研究时间为2016年1月-2018年1月,研究对象为首都医科大学石景山教学医院住院治疗的晚期卵巢癌患者共60例,依据随机数字表法分为两组(观察组和对照组各30例)。对照组予以放疗联合化疗,观察组予以放化疗联合贝伐珠单抗靶向治疗。比较两组治疗效果、毒副反应、血清肿瘤标志物水平及术后3年内生存率。结果:观察组治疗有效率高于对照组,差异有统计学意义(P<0.05);两组毒副反应发生率比较,差异无统计学意义(P>0.05);观察组随访1、3年内生存率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组VEGF、IL-6、AFP、CA125水平低于对照组,差异有统计学意义(P<0.05)。结论:放化疗联合贝伐珠单抗靶向治疗晚期卵巢癌患者具有良好效果,能有效提高患者术后3年内生存率,降低患者血清肿瘤标志物水平,同时安全性尚可,值得推广。
Objective:To study the clinical effect of radiotherapy and chemotherapy combined with Bevacizumab targeted therapy in patients with advanced ovarian cancer.Method:The design research time was from January 2016 to January 2018.The research objects were 60 patients with advanced ovarian cancer who were hospitalized in Shijingshan Teaching Hospital of Capital Medical University and were divided into two groups(30 cases in the observation group and 30 cases in the control group)according to the random number table method.The control group was given radiotherapy and chemotherapy,and the observation group was given radiotherapy and chemotherapy combined with Bevacizumab targeted therapy.The therapeutic effects,toxic and side effects,the level of serum tumor markers and survival rate within 3 years of follow-up of the two groups were compared.Result:The treatment effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05);there was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05);the survival rates within 1 and 3 years of follow-up in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of VEGF,IL-6,AFP and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:Radiotherapy and chemotherapy combined with Bevacizumab has a good effect in the targeted treatment of patients with advanced ovarian cancer.It can effectively improve the survival rate within 3 years and reduce the level of serum tumor markers.At the same time,it is safe and worthy of popularization.
作者
邓颖慧
DENG Yinghui(Shijingshan Teaching Hospital of Capital Medical University,Beijing 100043,China)
出处
《中外医学研究》
2022年第15期34-37,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
晚期卵巢癌
放疗
化疗
靶向治疗
贝伐珠单抗
血清肿瘤标志物
Advanced ovarian cancer
Radiotherapy
Chemotherapy
Targeted therapy
Bevacizumab
Serum tumor markers
